Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/5/2024 | $12.00 | Perform → Outperform | Oppenheimer |
| 9/25/2023 | $19.00 | Buy | H.C. Wainwright |
| 4/17/2023 | $14.00 → $13.00 | Strong Buy → Outperform | Raymond James |
| 10/15/2021 | $28.00 → $37.00 | Hold → Buy | Canaccord Genuity |
| 8/20/2021 | Perform | Oppenheimer | |
| 7/14/2021 | $24.00 → $28.00 | Hold | Canaccord Genuity |
| 7/9/2021 | $27.00 → $32.00 | Strong Buy | Raymond James |
Oppenheimer upgraded AngioDynamics from Perform to Outperform and set a new price target of $12.00
H.C. Wainwright initiated coverage of AngioDynamics with a rating of Buy and set a new price target of $19.00
Raymond James downgraded AngioDynamics from Strong Buy to Outperform and set a new price target of $13.00 from $14.00 previously
8-K - ANGIODYNAMICS INC (0001275187) (Filer)
10-Q - ANGIODYNAMICS INC (0001275187) (Filer)
8-K - ANGIODYNAMICS INC (0001275187) (Filer)
Investigator initiated trial seeks to validate safety, efficacy of the NanoKnife System in treating targeted tumors while reducing or delaying need for radical intervention AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the launch of an international multi-center prospective registry study to assess the long term effects of treating men with unifocal intermediate-risk prostate cancer with the NanoKnife® System in partnership with the University College London Hospital (UCLH). Approximate
New Codes Expand Market Access to Treatment with the NanoKnife® System AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that IRE has received CPT® Category I codes for the treatment of lesions in the prostate and liver. The decision by the American Medical Association's ("AMA") CPT® Editorial Panel will facilitate reimbursement for healthcare providers performing IRE ablation procedures and enables broader access to the NanoKnife System for patients. The new codes will be effective, with p
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2025, which ended August 31, 2024. Fiscal Year 2025 First Quarter Highlights Quarter Ended August 31, 2024 Pro Forma* YoY Growth Net Sales $67.5 million 1.1% Med Tech Net Sales $28.0 million 8.7% Med Device Net Sales $39.5 million (3.6)% GAAP gross margin of 54.4% GAAP loss per share of $0.31 Adjusted loss per share of $0.11 Sub
SC 13G - ANGIODYNAMICS INC (0001275187) (Subject)
SC 13G/A - ANGIODYNAMICS INC (0001275187) (Subject)
SC 13G/A - ANGIODYNAMICS INC (0001275187) (Subject)
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced the appointment of Lorinda Burgess to the Company's Board of Directors. Ms. Burgess brings over 35 years of management, financial, and global operations experience, including over 15 years at Medtronic, Inc., where she was responsible for the company's Americas Region as CFO, Vice President of Finance. While at Medtronic, Ms. Burgess led optimization initiatives that drove operational efficiencies and significant cost reductions. "Ms
PAVmed Inc. (NASDAQ:PAVM, PAVMZ))) (the "Company" or "PAVmed"), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid"), today announced the appointment of Shaun O'Neil to serve as Executive Vice President and Chief Operating Officer, overseeing diverse corporate operations and commercial activities across the Company and its subsidiaries. Mr. O'Neil has served as PAVmed's Chief Commercial Officer and Executive Vice President, Business Development since joining the Company in 2018. He will serve on the Company's Executive Committee and as an executive officer pursuant to Section 16(a) of the Securities
VALENCIA, Calif. and MELBOURNE, Australia, June 01, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))) ("AVITA Medical"), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of James Corbett and Jan Stern Reed to its Board of Directors effective July 1, 2021. Mr. Corbett has approximately 40 years of leadership experience in the medical device field, most recently, as CEO of CathWorks Ltd., a software-based medical technology company. Mr. Corbett has extensive global commercial and operating experience, serving as an
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2025, which ended August 31, 2024. Fiscal Year 2025 First Quarter Highlights Quarter Ended August 31, 2024 Pro Forma* YoY Growth Net Sales $67.5 million 1.1% Med Tech Net Sales $28.0 million 8.7% Med Device Net Sales $39.5 million (3.6)% GAAP gross margin of 54.4% GAAP loss per share of $0.31 Adjusted loss per share of $0.11 Sub
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market open on Thursday, October 3, 2024. The Company's management will host a conference call at 8:00 am ET the same day to discuss the results. To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international). This conference call will also be webcast and can be accessed from the "Investors" section of the Angi
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourth quarter and fiscal year 2024, which ended May 31, 2024. Fiscal Year 2024 Fourth Quarter Highlights Quarter Ended May 31, 2024 Pro Forma* YoY Growth Pro Forma* Net Sales $71.1 million 1.9% Med Tech Net Sales $29.3 million 11.3% Med Device Net Sales $41.8 million (3.8)% GAAP Gross margin of 54.3% GAAP loss per sh
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
Canaccord Genuity analyst William Plovanic maintains AngioDynamics (NASDAQ:ANGO) with a Buy and lowers the price target from $18 to $13.
HC Wainwright & Co. analyst Yi Chen reiterates AngioDynamics (NASDAQ:ANGO) with a Buy and maintains $14 price target.
U.S. stocks traded mostly higher toward the end of trading, with the Dow Jones index surging more than 650 points on Tuesday. The Dow traded up 1.63% to 40,865.59 while the NASDAQ fell 0.11% to 18,452.31. The S&P 500 also rose, gaining, 0.37% to 5,652.28. Check This Out: Wall Street’s Most Accurate Analysts Weigh In On 3 Industrials Stocks Delivering High-Dividend Yields Leading and Lagging SectorsIndustrials shares jumped by 2.3% on Tuesday. In trading on Tuesday, information technology shares fell by 0.8%. Top Headline Morgan Stanley (NYSE:MS) reported better-than-expected second-quarter results. Morgan Stanley reported second-quarter EPS of $1.82, up from $1.24 a yea